Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival
| Autor: | Jean Emond, Y. Lacoursière, André Dupont, Fernand Labrie, V. Bergeron, A. Bélanger, Gerard Monfette, M. Giguere |
|---|---|
| Rok vydání: | 1985 |
| Předmět: |
Oncology
Male medicine.medical_specialty Combination therapy medicine.drug_class Acid Phosphatase Urology Bone Neoplasms Antiandrogen Biochemistry Bone and Bones Flutamide law.invention Gonadotropin-Releasing Hormone chemistry.chemical_compound Prostate cancer Endocrinology Pharmacotherapy Randomized controlled trial law Internal medicine medicine Humans Anilides Testosterone Orchiectomy Radionuclide Imaging business.industry Dehydroepiandrosterone Sulfate Prostatic Neoplasms Dehydroepiandrosterone medicine.disease Castration chemistry Drug Therapy Combination business |
| Zdroj: | Journal of steroid biochemistry. 23(5B) |
| ISSN: | 0022-4731 |
| Popis: | Eighty-seven previously untreated patients with clinical stage D2 (bone metastases) prostate cancer have received the combination therapy with a pure antiandrogen and an LHRH agonist (or orchiectomy) as first treatment in a multicentre study for up to 34 months (average = 16.2 months). A positive objective response assessed according to the criteria of the US NPCP has been observed in all cases. Pain disappeared in all patients within 1 month and performance become normal in all (including 2 bedridden patients) within 4 months. Progression of the disease after a period of remission has been observed in only 8 patients. Only one patient has died from prostate cancer while 3 have died from other causes. The probability of continuing response and survival at 2 years for the patients who receive the combination treatment (Kaplan-Meier's method) is 81 and 91%, respectively. By contrast, in the randomized group who had orchiectomy alone, 4 of 7 have died from prostate cancer (P less than 0.05 as compared to combination therapy). In addition to a marked improvement in the remission rate and survival, combination therapy maintains a good quality of life, hot flashes and a decrease or loss of libido being the only side-effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|